PAO Group, Inc. (PAOG) has made substantial strides in several independent evaluations of RespRx research for the Chronic Obstructive Pulmonary Disease (COPD) treatment and to help prepare the cannabis drug to engage with a contract research organization (CRO) and, in turn, accelerate the application of an investigational New Drug (IND) in conjunction with Food and Drug Administration (FDA). PAOG expects some announcements of independent research engagement in the next few weeks.
The company got RespRx from pharmaceutical firm Kali-Extracts, Inc. on July 30, 2020. Cannabis drug RespRx, still under research for COPD treatment, is obtained from a copyrighted cannabis extraction technique titled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”
RespRx has depicted influence in raising the inspiratory airflow speed, tidal volume, and respiration rate in a previous scientific review for treating COPD. Data from the review indicated the drug could enhance the lung’s inspiratory functioning in temperate pulmonary fibrosis cases.
PAOG has now partnered with several new experts drawn from the commercial medical study community and the university to assess the RespRx formula, test results, and the formulation process.
The professional review has evaluated RespRx together with other cannabis treatment studies that are in the public domain. Two of those studies which show the research behind cannabinoid treatment by GW Pharmaceuticals provide more insights into the extensive chance PAOG has starting from RespRx, its extraction process, and the laboratory tests behind the drug.
One research concentrated on THC while the other on CBD. The studies appear to suggest that CBD affects the arousal of bodily responses that are key in eliminating bad cells and hyper-immune responses, which may give rise to conditions such as cytokine storm, a physiological reaction linked to COVID-19 mortalities. To some extent, the THC data supports RespRx ability to alleviate pain and capabilities of immune response manipulation to stimulate immune responses to eliminate bad cells and involve anti-inflammatory reactions.
In a nutshell, the publicly available study on cannabis treatment corroborates the research outcomes behind RespRx and concurrently elucidates the wider potential of the company’s RespRx inclusive technology.
The cannabis study body is establishing conclusive evidence on how particular cannabinoids can positively impact certain immune responses. The research shows how the RespRx extraction process can be altered to aim at particular cannabinoid extractions.
PAOG is confident it can use the cannabis extraction process to obtain formals with a dense concentration of specific cannabinoids, especially now that cannabis research reveals more proof on how certain cannabinoids positively influence specific immune responses. PAOG, therefore, looks at an extensive future of manufacturing cannabis treatments besides COPD.
Recently, PAOG also obtained business from Puration, Inc. to cultivate hemp for developing proprietary cultivar to back the firm’s cannabis pharmaceutical curative goals.
PAOG and PURA have plans to develop a proprietary hemp cultivar to expand PAOG’s hemp growing business. The two companies are partnering on Farmersville Brands’ initiative to construct a pharmaceutical hemp cultivar facility.
The Farmersville site will have a laboratory and an interior growing facility that is environmentally controlled. PAOG is at the moment working with contemporary cultivars to develop the best plant with full-spectrum, great CBD yields to fortify the current development of RespRx as well as to back CBD pharmaceutical developments in the future.
PAOG is also looking for ways to involve university research in collaboration to develop hemp cultivar.
PURA recently announced a full-year initiative to move from manufacturing CBD sports beverage to a wide range of CBD consumer products and become a hemp conglomerate. As part of the Farmersville Brands strategy, PURA got 72 acres of land in Farmersville, Texas, through a letter of intent agreement and planned to infuse the strategy with $100 million.